Matthew Zibelman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses the future of combination immunotherapies for patients with renal cell carcinoma, and talks on some of the key unmet needs and research gaps in this field. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

свернуть